STOCKHOLM, Sept. 23, 2021 /PRNewswire/ -- The first preclinical study, where the adjuvant technology Endocine has been evaluated with a vaccine candidate against COVID-19, shows positive results.
In May 2021, Eurocine Vaccine signed an evaluation agreement with an innovative North American company with the ambition to evaluate Endocine along with their vaccine candidate against COVID-19.
The first study in a mouse model indicates positive results with our adjuvant Endocine, where antibodies of both type IgA and IgG could be detected, as well as T cell immunity.
The North American company now intends to proceed with additional studies where Eurocine Vaccines will deliver Endocine and assist with knowledge and experience within the area.
Read more about our adjuvant:
https://www.eurocine-vaccines.com/the-portfolio/
CONTACT:
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/11552/3420508/1472292.pdf | Positive results with Endocine' and a vaccine candidate against COVID-19 |
